Innoviva, Inc. (INVA) — closed signal from March 12, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 10, 2026 — +3.7% at the close.
Predicted vs. what happened
What happened
Reached 51% of the predicted growth at its peak, without hitting the target.
The thesis — published March 12, 2026
INVA is a steadier biotech idea because it earns money from both royalties and its own drugs. A higher analyst target and the valuation case suggest upside, but trading is thin so moves can be slow. Be patient: if buyers keep the stock in the low-$20s, the next quarterly results could help the stock move higher.
Primary drivers
- Royalties plus owned drugs give more stable income
- Higher analyst target adds interest from buyers
- Recent pullback makes buying levels more favorable
- Less likely to swing wildly like single-drug biotechs
How it played out
INVA: target was not reached by June 10
Lyra published INVA on March 12 at $22.19 as a short-term thesis with expected growth of 20%. The thesis pointed to royalties plus owned drugs, a higher analyst target, a recent pullback, and a view that the stock was less likely to swing like single-drug biotechs. The target was $26.63.
Inside the window, INVA rose to a peak of $24.45 on April 20, a 10.2% gain. It never reached the target. By June 10, the stock ended at $23. The thesis partially played out because the stock rose, but the move stayed below the published target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.